• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pirtobrutinib in the BRUIN CLL-321 Study

Opinion
Video

Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.

Video content above is prompted by the following:

  • During the 2024 American Society of Hematology annual meeting, the phase 3 BRUIN CLL-321 study looking at the noncovalent BTK inhibitor pirtobrutinib was presented. Provide a brief review of the methodology of the BRUIN CLL-321 study.
  • What key takeaways from BRUIN CLL-321 suggest pirtobrutinib’s potential to address unmet needs in heavily pretreated relapsed/refractory CLL patients?
  • How does the tolerability data from BRUIN CLL-321 inform strategies for managing adverse events in patients receiving pirtobrutinib?
Related Videos
1 expert is featured in this series.
5 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.